Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call
November 15 2021 - 7:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye,
today announced that it has changed the time of its previously
scheduled financial results conference call and live audio webcast.
The Company will now report its third quarter 2021 financial
results and provide a business update on Monday, November 15th at
10:30 am. ET.
The dial-in numbers to access the conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 7298039. To access a live webcast and subsequent
archived recording of the call, please visit “Events” in the
“Investor” section on the Kala website
at http://kalarx.com/.
About Kala Pharmaceuticals,
Inc.
Kala is a commercial-stage biopharmaceutical company focused on
the discovery, development, and commercialization of innovative
therapies for diseases of the eye. Kala has applied its AMPPLIFY®
mucus-penetrating particle (MPP) Drug Delivery Technology to two
ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic
suspension) 0.25% for the short-term (up to two weeks) treatment of
signs and symptoms of dry eye disease and INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% for the treatment of
post-operative inflammation and pain following ocular surgery. The
Company also has a pipeline of pre-clinical development programs
targeted to address unmet medical needs, including both front and
back of the eye diseases. For more information on Kala, please
visit www.kalarx.com.
Investor Contacts: Jill
Steierjill.steier@kalarx.com781-996-5252
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024